Stakhovsky Е.О.1, Tymoshenko A.V.2, Voilenko O.A.1, Vitruk Yu.V.1, Kononenko O.A.1, Chekhun V.F.2

Aim: to assess the metabolic syndrome (MS) effect on progression of local prostate cancer (PC) with intermediate and high progression risk after radical prostatectomy (RP). Object and methods: The study included 106 patients with benign and malignant neoplasms of the prostate with the average age of 61.3 ± 5.4 years, who underwent inpatient treatment and follow-up at the National Cancer Institute. Eighty-one patients were diagnosed with local prostate cancer stage II-III, Grade group (GG) 2–5; 25 patients had benign prostatic hyperplasia (BPH). The patients were divided into 3 groups: 1 group — patients with intermediate progression risk, GG 2–3; group 2 — patients with high progression risk, GG 4-5; patients with BPH were in the control group. The patients underwent radical prostatectomy with standard pelvic lymph dissection or Stakhovsky adenomectomy/transurethral resection of the prostate based on medical indications. Before the surgery and every 3 months after it, patients were examined using general clinical, biochemical and instrumental methods. Statistical analysis of the results was performed based on the approaches of variation statistics using Statistica 6.0 software. Differences at p<0.05 were considered as statistically significant. Results: according to the international criteria for determining the MS, examined patients were divided into two groups: MS+ (n = 52; 49.0%) and MS (n = 54; 51.0%). In the patients with MS, disease prolongation with the development of bone metastases was registered in 26.3% patients in the group I (PC, GG 2–3) and in 61.9% patients in the group II (PC, GG 4–5) versus 14.2% (group I) and 45% (group II) patients without MS. In the group I, the time to bone metastasis appearance was 39.1 months in MS+ versus 44.3 months in MS patients. In the group II (patients with high progression risk), the development of bone metastases in MS+ and MS patients was registered after, respectively, 11.6 and 14.5 months post-operatively. Conclusions: the obtained results point to the impact of MS on the development of PC bone metastases. Meanwhile, MS does not affect the development of biochemical relapse in these patients.

No comments » Add comment